Breakout-Companion Soothing Line: The Cosmetic-Clean Companion Layer for Actives Routines

Actives own the breakout shelf, and the soothing layer beside them is thin — where it exists at all, the claim line is usually wrong. This playbook covers the science, the line architecture, the QC panel and the claims route.

01 · The problem

Breakout care is an actives war — effective and harsh. What the routine lacks is the companion layer: products that soothe the visible stress those actives cause. Most brands miss twice: they underdeliver (a plain moisturizer) or overclaim (treatment language that reads as a drug on paper). The companion slot sells — and it is exactly where the claim risk sits.

02 · Scientific rationale

The formulation logic is soothing support for skin undergoing active treatment: characterized EV material with calming-signal literature, in low-sting bases, fragrance-minimal. The claims are the real spec here: companion positioning (used alongside prescribed routines), appearance-level wording only (visibly soothed, calmer-looking), and no treatment language. That combination keeps the line cosmetic in both the EU and the US.

03 · Program documentation

Protocol documentation for this program family is maintained in TONGNIAN's internal files — network-clinic protocol series and anonymized case records where applicable [5]. Partner access under NDA; the evidence hierarchy stays explicit — published reviews first, internal observational programs second, case documentation third. [6]

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line — closed-tubing culture, scheduled harvest, tangential-flow separation and concentration, sterile filtration — with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [3].

Fig. 1 — The companion architecture: daily, on-the-go, point-care.

06 · Regulatory pathway: EU & US first

EU cosmetic track (CPNP, CPSR) and US MoCRA. On-pack copy avoids condition naming entirely — shelf communication says breakout-prone skin routines. Material chain: DMF Type II 044197, INCI 41316. China market entry later on the same basis.

07 · Expected outcomes

• A companion shelf position that actives brands want next to their products.
• Compliance-clean by design: companion positioning and appearance-level wording keep the line on the cosmetic track in the EU and the US.
• Line economics: three SKUs (essence, spray, point care) cover the full routine, and each stays inside the cosmetic claim line.

No claims are made beyond the cosmetic, supplement, or professional-use framing of the destination market — authority comes from documentation and batch measurement.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label and program naming run through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Systematic review of 19 human studies of topical exosome skin applications, 2026 — summary via DermatologyNews.net.
3. Grand Ingredients. Exosome-Mimetic Systems 2026; The Technical Reality of Exosomes Beyond Particle Counts.
4. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17), national standard — TONGNIAN, drafting organization.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).